Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Soap-and-Water Bed Bath Versus Disposable Wipe Bath in the Same ICU Patients (YBU-BANYO)

30 de octubre de 2026 actualizado por: Ozhan Ozcan, Sinop Atatürk State Hospital

Within-Patient Comparison of Traditional Soap-and-Water Bed Bath and Disposable No-Rinse Wipe Bath on Procedural Pain Behavior, Comfort and Physiological Response in Adult Intensive Care Unit Patients: A Randomized Crossover Trial

Bed bathing is a routine nursing procedure in the intensive care unit (ICU). In the study units, every patient routinely receives both a traditional bed bath with warm water and soap (every 10 days) and a bath with pre-packaged, disposable, no-rinse wipes (every 3 days). Little is known about how these two methods compare for pain, comfort and physiological stress in the same patient.

The goal of this randomized crossover trial is to compare the two bathing methods within the same adult ICU patients. The main question it aims to answer is: Does pain-related behavior during the bath, measured with the Critical-Care Pain Observation Tool (CPOT) while the patient is turned to the side, differ between the soap-and-water bath and the wipe bath? Other questions include whether the methods differ in vital signs and body temperature after the bath, anxiety, comfort, feeling of cleanliness, satisfaction and preference in patients who can self-report, bath duration, nursing time, cost, and adverse events.

The routine bathing schedule does not change. Only the order of each participant's first two study baths is decided by chance: either soap-and-water first and wipes 72 hours later, or wipes first and soap-and-water 72 hours later. Each patient serves as his or her own control. The first minute of the first lateral turn in both baths is video-recorded (face, upper body and arms only) and scored by an assessor who does not know which method was used.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

Design: Single-center, prospective, randomized, two-period, two-sequence (wash-wipe / wipe-wash) crossover trial embedded in routine care, with blinded video-based assessment of the primary outcome. Setting: second-level (16 beds) and third-level (22 beds) adult ICUs, Sinop Atatürk State Hospital, Türkiye.

Routine care and schedule: All ICU patients routinely receive a whole-body soap-and-water bed bath every 10 days and a whole-body disposable wipe bath every 3 days. In the study, Session 1 is given within 24 hours after randomization with the method determined by the allocated sequence, and Session 2 is given with the other method 72 hours (±12 hours) later, which matches the routine 3-day interval. Thereafter, the routine schedule continues (soap-and-water every 10 days from the first wash; wipes every 3 days; if both fall on the same day, only the soap-and-water bath is given). Routine oral and perineal care continues. Additional baths are allowed when clinically needed.

Randomization: Sequences are allocated 1:1 using computer-generated lists with permuted blocks of 4 and 6, stratified by ICU level and communication status (Stratum A: able to self-report - RASS -1 to +1, CAM-ICU negative, able to use a visual analogue scale; Stratum B: unable to self-report). Allocation is concealed with sequentially numbered, opaque, sealed envelopes.

Interventions: Both methods cover the whole body in the same clean-to-dirty order with two lateral turns, two nurses, privacy measures, linen change and a standardized information script. Soap-and-water bath: warm water (43.5-46 °C), liquid soap, separate cloths and towels; each area is soaped, rinsed and towel-dried. Wipe bath: chlorhexidine-free, no-rinse disposable wipes warmed to ≤40 °C; a new wipe for each area, at least three passes with light pressure, air-dried.

Measurements: Full measurements are made in Sessions 1 and 2 at T0 (before the bath after ≥15 minutes of rest), during the bath, T1 (10 minutes after), T2 (30 minutes after) and during the 2 hours after the bath. CPOT and vital signs are recorded in all patients; Stratum A patients also rate anxiety (VAS-A), comfort, cleanliness and satisfaction, and state their preferred method after Session 2. For later routine baths, date, method, duration, materials and adverse events are recorded; skin is assessed at baseline, at each soap-and-water bath and at ICU discharge (descriptive only, because every patient receives both methods).

Blinding: The first minute of the first lateral turn in Sessions 1 and 2 is video-recorded with a hospital-owned, password-protected device (face, upper body and arms; ventilator screen in intubated patients; bathing materials and genital area excluded). Videos are coded without method or session information and scored in random order by an assessor not involved in bathing. The muscle tension item is taken from the in-room nurse. If no video is available, the in-room CPOT score is used. Videos are deleted after scoring.

Sample size: Assuming a clinically relevant within-patient difference of 1 CPOT point and a standard deviation of differences of 2.0 (dz = 0.5), two-sided alpha 0.05 and 80% power, 34 patients completing both sessions are required. Allowing about 15% loss before Session 2, 40 patients will be randomized.

Statistical analysis: Procedural CPOT will be analyzed with a linear mixed model including method, period, sequence and session-specific resting CPOT as fixed effects and patient as a random effect, adjusted for ICU level and stratum; all randomized patients contribute available data. Sensitivity analyses: Wilcoxon signed-rank test with Hodges-Lehmann estimate in completers, in-room scores, video-only sessions, adjustment for sedative infusions, and an ordinal mixed model. Secondary outcomes are analyzed with mixed models, McNemar tests or exact binomial test (preference), and interpreted as exploratory.

Safety: The bath is stopped if SpO2 < 90% for >1 minute, MAP < 65 mmHg or >20% fall, heart rate >130 or <50/min or new arrhythmia, RASS ≥ +2, tube or catheter displacement, or at the patient's request.

Tipo de estudio

De observación

Inscripción (Estimado)

72

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

Age 18 years or older. Admitted to the second- or third-level adult ICU within the previous 48 hours and expected to stay at least another 24 hours

Descripción

Inclusion Criteria:

  • Age 18 years or older
  • Admitted to the second- or third-level adult ICU within the previous 48 hours and expected to stay at least another 24 hours
  • Richmond Agitation-Sedation Scale (RASS) score between -3 and +1
  • Judged by the attending physician to be clinically suitable for a whole-body bed bath with two lateral turns
  • Hemodynamically stable: no vasopressor, or norepinephrine ≤ 0.1 µg/kg/min (or equivalent) without dose increase in the previous 6 hours
  • Written informed consent from the patient or the legal representative

Exclusion Criteria:

  • RASS ≤ -4 or ≥ +2
  • Use of neuromuscular blocking agents
  • End-of-life or exclusively palliative care
  • Severe neurological injury (brain death, Glasgow Coma Scale ≤ 8 not due to sedation)
  • Extensive skin damage (burns, widespread dermatitis, large open wounds) or known allergy to the wipe ingredients
  • Open abdomen, unstable spinal fracture, ECMO or any other condition preventing lateral turning
  • Initiation or dose change of anxiolytic or antipsychotic treatment within the previous 24 hours
  • Previous participation in this study within the last 30 days

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Soap-and-Water Bed Bath

Whole-body bed bath with warm water (43.5-46 °C) and liquid soap; each body area is soaped, rinsed and towel-dried; two lateral turns, two nurses. First bath within 24 hours after randomization, then every 10 days until ICU discharge.

Disposable Wipe Bath

Whole-body bed bath with pre-packaged, chlorhexidine-free, no-rinse disposable wipes warmed to ≤40 °C; a new wipe for each body area, no rinsing or towel-drying; two lateral turns, two nurses. Same schedule as the comparator arm.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Procedural pain behavior during the first lateral turn (CPOT)
Periodo de tiempo: During the first study bath, at the first lateral turn (within 24 hours after randomization)

Critical-Care Pain Observation Tool (CPOT) total score (range 0-8; higher scores indicate more pain-related behavior), scored from a video recording of the first minute of the first lateral turn by an assessor blinded to group allocation. Compared between groups adjusted for resting CPOT at T0.

During the first study bath, at the first lateral turn (within 24 hours after randomization)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of patients with significant pain behavior during the bath
Periodo de tiempo: During the first study bath (within 24 hours after randomization)

Proportion of patients with procedural CPOT score > 2 (range 0-8) during the first lateral turn of the first study bath.

During the first study bath (within 24 hours after randomization)
Post-bath CPOT score
Periodo de tiempo: 10 and 30 minutes after the end of the first study bath

CPOT total score (0-8; higher = more pain-related behavior), adjusted for resting CPOT.

10 and 30 minutes after the end of the first study bath
Anxiety in patients able to self-report
Periodo de tiempo: 10 and 30 minutes after the end of the first study bath

Visual analogue scale for anxiety (VAS-A; 0-10 cm; higher = more anxiety) in Stratum A patients, adjusted for the pre-bath score.

10 and 30 minutes after the end of the first study bath
Comfort, cleanliness and satisfaction in patients able to self-report
Periodo de tiempo: 10 minutes after the end of the first study bath

Numeric rating scales (0-10; higher = better) for comfort, feeling clean and fresh, and satisfaction with the bath, in Stratum A patients

10 minutes after the end of the first study bath

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

10 de noviembre de 2026

Finalización primaria (Estimado)

10 de febrero de 2027

Finalización del estudio (Estimado)

10 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

30 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

30 de octubre de 2026

Publicado por primera vez (Actual)

5 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

De-identified individual participant data underlying the published results may be made available upon reasonable request to the principal investigator after publication, subject to approval by the ethics committee and in compliance with Turkish Personal Data Protection Law No. 6698. Video recordings will not be shared and will be deleted after scoring.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir